Using breath analysis to predict mouth sores from radiotherapy in head and neck cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the use of breath analysis to diagnose and predict radiotherapy-induced oropharyngeal mucositis in patients with head and neck tumors. By collecting exhaled breath samples, researchers will analyze volatile organic compounds (VOCs) to identify potential biomarkers for this painful side effect of treatment. The goal is to develop a non-invasive diagnostic model that can provide early detection and improve patient management during radiotherapy. This approach aims to enhance the quality of life for patients by addressing the limitations of current diagnostic methods.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Voluntarily sign informed consent. Over 18 years of age. Histologically confirmed head and neck tumors, treated with radiotherapy or chemoradiotherapy.

ECOG PS Score: 0/1/2.

Exclusion Criteria:

* Lung disease such as lung cancer, tuberculosis, and lung infections. Inhalation anesthesia within 3 months. Inhalation medication within 3 months. Postoperative laryngeal cancer. Concurrent serious uncontrolled medical conditions such as unstable heart disease requiring treatment, poorly controlled diabetes mellitus (fasting blood glucose \> 1.5 x upper limit of normal).

Participation deemed inappropriate in the judgment of the investigator.

Where it's running

• Nanfang hospital, Southern medical university
  Guangzhou, Guangdong, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding metal elements in radiation-induced mouth sores

  This study is trying to see if certain metal elements in the body can help predict how severe mouth sores will be for patients getting radiation treatment for head and neck cancer.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT06968520

• SI-B036 in head and neck and other solid tumors: a first-in-human study

  This early-phase study tests SI-B036 in adults with locally advanced or metastatic head and neck cancers and other solid tumors to see if it is safe and tolerable, and to get initial clues about its activity.

  Recruiting at 2 sites Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Changsha, Hunan and 1 other locations · NCT07763639

• LRRC15-targeted PET imaging for more precise diagnosis and staging of pancreatic, breast, lung, sarcoma and head-and-neck cancers

  This project tests whether an LRRC15-targeted PET scan can better detect and stage LRRC15-expressing cancers and measures how the tracer behaves in healthy adults.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07552467

• Traditional Chinese oral solution and mouthwash to shorten severe radiation-induced mouth sores in head and neck cancer.

  This trial will try a combined traditional Chinese oral solution and mouthwash to shorten and ease severe radiation-induced mouth sores in adults receiving radiotherapy for head and neck cancer.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT07339774

• Understanding how mutant p53/YAP proteins affect treatment resistance in head and neck cancer

  This study looks at how changes in certain proteins in head and neck cancer cells might make them resistant to treatment, helping doctors find better ways to fight the disease.

  Recruiting Regina Elena Cancer Institute · Roma, Rome · NCT06791941

• Targeted alpha therapy [212Pb]VMT-Alpha-NET for SSTR-positive metastatic or inoperable GI neuroendocrine, pheochromocytoma/paraganglioma, small cell lung, kidney, and head & neck cancers

  This trial will try an experimental targeted alpha-particle drug called [212Pb]VMT-Alpha-NET in adults whose metastatic or inoperable tumors show somatostatin receptor (SSTR) expression.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06479811

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.